Earlier in the year, Warner Chilcott sought treble damages, costs and a permanent injunction against Schering and its US affiliate, Berlex over the Yaz patent.
Under the settlement, Schering will make certain payments to Warner Chilcott in connection with the settlement. Financial terms were not disclosed. The terms of the agreements are subject to clearance by the Federal Trade Commission.
Yaz is a birth control pill indicated for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder, which is a severe form of premenstrual symptoms.
Warner Chilcott also said it licensed its treatment for inflammatory skin diseases to Scheirng. Warner Chilcott will pay a royalty to Schering on sales of any product containing the compound under the license.